Chao Fangfang, Zhang Hong
Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
J Biomed Biotechnol. 2012;2012:783739. doi: 10.1155/2012/783739. Epub 2012 Mar 7.
Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is emerging as a potential diagnosis and staging test in patients with non-small-cell lung cancer (NSCLC). The purpose of this paper is to discuss the value of integrated PET/CT in the staging of the non-small-cell lung cancer and its health economics.
肺癌是一种常见疾病,在许多国家都是癌症相关死亡的主要原因。非小细胞肺癌患者的精确分期在确定治疗策略和预后方面起着重要作用。正电子发射断层扫描/计算机断层扫描(PET/CT)结合了CT的解剖信息和PET的代谢信息,正在成为非小细胞肺癌(NSCLC)患者潜在的诊断和分期检查方法。本文旨在探讨PET/CT融合技术在非小细胞肺癌分期中的价值及其卫生经济学意义。